Latest On Aeglea BioTherapeutics, Inc (AGLE):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-11 16:23 EST | News | Aeglea BioTherapeutics GAAP EPS of -$0.20 misses by $0.03, revenue of $0.2M beats by $0.12M | N/A |  |
| 2023-04-12 14:03 EST | News | Aeglea slumps ~25% as trial results trigger strategic options, workforce reduction | N/A | |
| 2023-03-02 12:50 EST | News | Aeglea BioTherapeutics GAAP EPS of -$0.99 beats by $0.03, revenue of $2.33M beats by $0.1M | N/A | |
| 2022-11-30 13:09 EST | News | Aeglea BioTherapeutics names Jeffrey Goldberg as CEO; shares slide on corporate and clinical development strategy | N/A | |
| 2022-11-16 07:37 EST | News | Aeglea BioTherapeutics appoints Linda Neuman as chief medical officer | N/A | |
| 2022-11-15 14:55 EST | News | Aeglea Bio regains Nasdaq compliance | N/A | |
| 2022-10-28 12:08 EST | News | Aeglea BioTherapeutics upgraded to overweight at Wells Fargo on pegtarviliase optimism | N/A | |
| 2022-10-04 12:49 EST | News | Aeglea stock dips as FDA places partial hold on enrolling under 18 patients in metabolic disorder trial | N/A | |
| 2022-08-24 16:36 EST | News | Aeglea Bio announces departure of CEO, corporate restructuring | N/A | |
| 2022-08-19 10:33 EST | News | Aeglea stock jumps ~58% on EMA validation of marketing application for enzyme pegzilarginase | N/A | |
| 2022-08-04 23:04 EST | News | Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M | N/A | |
| 2022-06-02 21:23 EST | News | Aeglea BioTherapeutics receives FDA Refuse to File letter for pegzilarginase | N/A | |
| 2022-05-05 20:57 EST | News | Aeglea BioTherapeutics GAAP EPS of -$0.37, revenue of $1.36B | N/A | |
| 2022-05-05 20:57 EST | News | Aeglea BioTherapeutics to raise $45M in stock and warrants offering | N/A | |
| 2022-04-12 08:04 EST | News | Aeglea surges 40% following additional phase 3 data for pegzilarginase for rare disorder | N/A | |
| 2022-04-12 08:04 EST | News | Aeglea stock soars 24% on filing seeking FDA approval of pegzilarginase for rare disorder | N/A | |
| 2022-03-08 08:52 EST | News | Aeglea BioTherapeutics GAAP EPS of -$1.00 beats by $0.02, revenue of $18.73M beats by $1.33M | N/A | |
| 2022-02-10 22:39 EST | News | Aeglea director resigns after disagreement on financing plans | N/A | |
| 2021-12-10 09:55 EST | News | Warning: AGLE is at high risk of performing badly | N/A | |
| 2021-12-08 01:57 EST | News | Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower | N/A | |
| 2021-12-06 10:54 EST | News | Aeglea says pivotal trial for pegzilarginase in Arginase 1 Deficiency met main goal | N/A | |
| 2021-11-05 00:43 EST | News | Aeglea BioTherapeutics EPS misses by $0.01 | N/A | |
| 2021-09-21 11:24 EST | News | Aeglea BioTherapeutics (AGLE) Investor Presentation - Slideshow | N/A | |
| 2021-08-05 21:31 EST | News | Aeglea BioTherapeutics reports Q2 results | N/A | |
| 2021-07-20 18:23 EST | News | Aeglea Biotherapeutics doses first patient in early-stage AGLE-177 Homocystinuria study | N/A | |
| 2021-07-20 18:14 EST | News | Aeglea Biotherapeutics names Jonathan Alspaugh as chief financial officer | N/A | |
| 2021-07-20 18:07 EST | News | Aeglea posts 20 week data from early-stage pegzilarginase Arginase 1 Deficiency study | N/A | |
| 2021-05-03 17:28 EST | News | Aeglea completes patient randomization in late-stage pegzilarginase trial | N/A | |
| 2021-03-22 22:13 EST | News | Aeglea inks deal with Immedica for Europe, Middle East rights to rare disease therapy | N/A | |
| 2021-03-19 04:04 EST | Earnings Estimate | An EPS average of -$1.41 is estimated for the 2022 year. | Sell | |
| 2021-03-19 04:04 EST | Earnings Estimate | An EPS average of -$0.34 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-03-19 04:04 EST | Analyst Rating | The Analyst Target Price has increased from $14.14 to $14.29. | Buy | |
| 2021-03-18 13:31 EST | News | Aeglea BioTherapeutics EPS beats by $0.04 | N/A | |
| 2021-03-08 17:10 EST | News | Aeglea Biotherapeutics climbs 5.5% on ownership disclosure | N/A | |
| 2021-03-03 15:02 EST | Analyst Rating | The Analyst Target Price has decreased from $15.63 to $14.14. | Neutral | |
| 2021-02-04 09:10 EST | News | Aeglea Biotherapeutics CFO Charles York to step down | N/A | |
| 2021-01-06 02:18 EST | News | Aeglea again pushes back arginase 1 deficiency trial enrollment to March | N/A | |
| 2021-01-02 23:49 EST | News | Aeglea BioTherapeutics: Human Enzyme-Based Platform Tackles Multiple Rare Diseases | N/A | |
| 2020-12-13 03:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-01 09:55 EST | News | Aeglea Bio's ACN00177 nabs Rare Pediatric status for inherited metabolic disorder | N/A | |
| 2020-11-25 11:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-19 19:04 EST | Analyst Rating | The Analyst Target Price has decreased from $16.29 to $15.63. | Neutral | |
| 2020-11-10 19:04 EST | Analyst Rating | The Analyst Target Price has decreased from $16.57 to $16.29. | Neutral | |
| 2020-11-10 03:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 23:03 EST | Analyst Rating | The Analyst Target Price has decreased from $16.71 to $16.57. | Neutral | |
| 2020-11-06 11:03 EST | Earnings Estimate | An EPS average of -$0.36 is estimated for the quarter ending on March 31, 2021. | Sell | |
| 2020-11-06 01:51 EST | News | Aeglea BioTherapeutics EPS beats by $0.11 | N/A | |
| 2020-11-01 16:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-27 13:22 EST | News | Aeglea's ACN00177 nabs Orphan Drug tag in the U.S. and Europe for a metabolic disorder | N/A | |
| 2020-10-26 10:36 EST | News | Aeglea's ACN00177 nabs Orphan Drug tag ion the U.S. and Europe for a metabolic disorder | N/A | |
About Aeglea BioTherapeutics, Inc (AGLE):
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine; and AEB3103, a product candidate. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
General
- Name Aeglea BioTherapeutics, Inc
- Symbol AGLE
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 87
- Fiscal Year EndDecember
- IPO Date2016-04-07
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.aegleabio.com
View More
Valuation
- Price/Book (Most Recent Quarter) 2.73
View More
Financials
- Most Recent Quarter 2020-09-30
- Current Year EPS Estimate -$1.33
- Next Year EPS Estimate -$1.41
- Next Quarter EPS Estimate -$0.41
- Return on Assets -39%
- Return on Equity -74%
- Earnings Per Share -$2.30
- Revenue Per Share $0
- Gross Profit -64600000
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 358.57 million
- EBITDA -63472000
- PE Ratio -0.15
- Analyst Target Price $14.29
- Book Value Per Share $3.05
View More
Share Statistics
- Shares Outstanding 47.94 million
- Shares Float 31.64 million
- % Held by Insiders 253%
- % Held by Institutions 94.44%
- Shares Short 1.81 million
- Shares Short Prior Month 1.79 million
- Short Ratio 7.26
- Short % of Float 4%
- Short % of Shares Outstanding 4%
View More
Technicals
- Beta 1.69
- 52 Week High $11.38
- 52 Week Low $3.7
- 50 Day Moving Average 7.55
- 200 Day Moving Average 7.88
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Aeglea BioTherapeutics, Inc (AGLE) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Aeglea BioTherapeutics, Inc (AGLE) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | -$0.35 | -$0.31 | -12.9% | |
| 2020-09-30 | 2020-11-05 | $N/A | -$0.29 | -$0.40 | 27.26% |
| 2020-06-30 | 2020-08-10 | $N/A | -$0.40 | -$0.43 | 7.06% |
| 2020-03-31 | 2020-05-07 | $N/A | -$0.57 | -$0.66 | 13.19% |
| 2019-12-31 | 2020-02-24 | $N/A | -$0.65 | -$0.66 | 2.15% |
| 2019-09-30 | 2019-11-06 | $N/A | -$0.66 | -$0.53 | -23.99% |
| 2019-06-30 | 2019-08-06 | $N/A | -$0.55 | -$0.48 | -13.82% |
| 2019-03-31 | 2019-05-07 | $N/A | -$0.59 | -$0.55 | -6.85% |
| 2018-12-31 | 2019-03-07 | $3.89 million | -$0.62 | -$0.37 | -69.35% |
| 2018-09-30 | 2018-11-08 | $-2378000 | -$0.54 | -$0.43 | -25% |
| 2018-06-30 | 2018-08-09 | $2.38 million | -$0.46 | -$0.35 | -33.33% |
| 2018-03-31 | 2018-05-08 | $1.51 million | -$0.49 | -$0.46 | -6.41% |
| 2017-12-31 | 2018-03-13 | $1.48 million | -$0.39 | -$0.53 | 26.25% |
| 2017-09-30 | 2017-11-07 | $1.26 million | -$0.48 | -$0.55 | 12.89% |
| 2017-06-30 | 2017-08-09 | $1.48 million | -$0.47 | -$0.48 | 2.08% |
| 2017-03-31 | 2017-05-09 | $982000 | -$0.47 | -$0.47 | -0.45% |
| 2016-12-31 | 2017-03-23 | $1.25 million | -$0.33 | -$0.51 | 35.31% |
| 2016-09-30 | 2016-11-09 | $1.15 million | -$0.47 | -$0.54 | 13.57% |
| 2016-06-30 | 2016-08-09 | $1.37 million | -$0.46 | -$0.42 | -9.52% |
| 2016-03-31 | 2016-05-19 | $859000 | -$0.35 | -$0.49 | 27.63% |
Aeglea BioTherapeutics, Inc (AGLE) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | 64.6 million | N/A |
| Income Before Tax | N/A | N/A | N/A | -21.5 million | -21.57 million |
| Selling General Administrative | N/A | N/A | N/A | 4.34 million | 4.31 million |
| Gross Profit | N/A | N/A | N/A | -17.57 million | -17.84 million |
| Ebit | N/A | N/A | N/A | -21.91 million | -22.15 million |
| Operating Income | N/A | N/A | N/A | -21.91 million | -22.15 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | 17.57 million | 17.84 million |
| Total Other Income Expense Net | N/A | N/A | N/A | 414000 | 573000 |
| Net Income From Continuing Operations | N/A | N/A | N/A | -21.5 million | -21.57 million |
| Net Income Applicable to Common Shares | -18.03 million | -21.42 million | -18.73 million | -21.5 million | -21.57 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | 11.5 million | 16.16 million |
| Change to Liabilities | -1.86 million | 1.06 million | 262000 | 749000 | -307000 |
| Total Cash Flow from Investing Activities | 5.78 million | -56.76 million | 14.75 million | 10.33 million | 16.01 million |
| Net Borrowings | -6000 | -1000 | -7000 | -7000 | -6000 |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | 676000 | 311000 |
| Change to Operating Activities | 358000 | -1 million | -4.85 million | 3.08 million | 3.24 million |
| Change in Cash | N/A | N/A | N/A | -5.29 million | -885000 |
| Total Cash from Operating Activities | -17.54 million | -19.41 million | -21.69 million | -16.29 million | -17.21 million |
| Depreciation | N/A | N/A | N/A | 106000 | 105000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 1.75 million | 1.73 million | 1.47 million | 1.26 million | 1.32 million |
| Capital Expenditures | N/A | N/A | N/A | 1.17 million | 143000 |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 19.36 million | N/A | N/A | 23.1 million | 20.3 million |
| Total Stockholder Equity | 136.27 million | N/A | N/A | 60.08 million | 79.8 million |
| Other Current Liabilities | 607000 | N/A | N/A | N/A | 82000 |
| Total Assets | 155.63 million | N/A | N/A | 83.18 million | 100.1 million |
| Common Stock | 5000 | 5000 | 3000 | 3000 | 3000 |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -253.29 million | -235.26 million | -213.84 million | -195.12 million | -173.62 million |
| Other Liabilities | 4000 | 68000 | 23000 | 31000 | N/A |
| Other Assets | 1.62 million | 1.59 million | 1.56 million | 1.51 million | 1.55 million |
| Cash | 54.22 million | N/A | N/A | 19.25 million | 24.55 million |
| Total Current Liabilities | 14.35 million | N/A | N/A | 18.36 million | 15.4 million |
| Other Stockholder Equity | 20000 | 39000 | -134000 | 51000 | 78000 |
| Property, Plant & Equipment | 9.61 million | 9.45 million | 8.96 million | 7.17 million | 5.92 million |
| Total Current Assets | 144.4 million | N/A | N/A | 74.51 million | 92.63 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 136.27 million | 152.26 million | 42.81 million | 60.08 million | 79.8 million |
| Short Term Investments | 85.75 million | N/A | N/A | 52.7 million | 64.16 million |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 2.3 million | N/A | N/A | 3.15 million | 2.43 million |
Aeglea BioTherapeutics, Inc (AGLE) Chart:
Aeglea BioTherapeutics, Inc (AGLE) News:
Below you will find a list of latest news for Aeglea BioTherapeutics, Inc (AGLE) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Aeglea BioTherapeutics, Inc (AGLE) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest AGLE Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:51 PM EST | 100 | $0.7376 |
| Jun 13, 2022 7:52 PM EST | 100 | $0.738 |
| Jun 13, 2022 7:56 PM EST | 100 | $0.7378 |
| Jun 13, 2022 7:57 PM EST | 100 | $0.7373 |
| Jun 13, 2022 7:59 PM EST | 100 | $0.7366 |
Aeglea BioTherapeutics, Inc (AGLE) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000120919120035528/0001209191-20-035528-index.htm |
| 2019-02-04 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1636282/000000000019000882/0000000000-19-000882-index.htm |
| 2020-07-10 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1636282/000000000020006223/0000000000-20-006223-index.htm |
| 2019-01-31 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000005341719000004/0000053417-19-000004-index.htm |
| 2020-02-03 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000005341720000005/0000053417-20-000005-index.htm |
| 2019-02-08 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000021545719006615/0000215457-19-006615-index.htm |
| 2020-02-05 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000083423720004706/0000834237-20-004706-index.htm |
| 2020-05-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000083423720009474/0000834237-20-009474-index.htm |
| 2020-10-26 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000089914020000490/0000899140-20-000490-index.htm |
| 2018-10-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000090266418003697/0000902664-18-003697-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000090266420000951/0000902664-20-000951-index.htm |
| 2019-02-05 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000110465919005826/0001104659-19-005826-index.htm |
| 2020-01-30 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000110465920008697/0001104659-20-008697-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000110465920020194/0001104659-20-020194-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000110465920020224/0001104659-20-020224-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000110465920021749/0001104659-20-021749-index.htm |
| 2019-01-31 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000113777419000028/0001137774-19-000028-index.htm |
| 2020-02-06 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000113777420000050/0001137774-20-000050-index.htm |
| 2018-07-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000114036118032316/0001140361-18-032316-index.htm |
| 2018-07-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000114036118032462/0001140361-18-032462-index.htm |
| 2018-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000114036118032715/0001140361-18-032715-index.htm |
| 2018-07-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000114036118032716/0001140361-18-032716-index.htm |
| 2018-07-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000114036118033053/0001140361-18-033053-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000114420419007215/0001144204-19-007215-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000114420419007503/0001144204-19-007503-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000114420419008123/0001144204-19-008123-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000117266119000427/0001172661-19-000427-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000117266120000648/0001172661-20-000648-index.htm |
| 2018-12-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000119312518356308/0001193125-18-356308-index.htm |
| 2018-12-21 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1636282/000119312518356318/0001193125-18-356318-index.htm |
| 2019-02-05 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1636282/000119312519028366/0001193125-19-028366-index.htm |
| 2019-02-07 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1636282/000119312519029933/0001193125-19-029933-index.htm |
| 2019-02-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000119312519029935/0001193125-19-029935-index.htm |
| 2019-02-11 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1636282/000119312519034157/0001193125-19-034157-index.htm |
| 2019-02-11 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1636282/000119312519034172/0001193125-19-034172-index.htm |
| 2019-02-13 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1636282/000119312519038115/0001193125-19-038115-index.htm |
| 2020-04-16 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1636282/000119312520108746/0001193125-20-108746-index.htm |
| 2020-04-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000119312520108751/0001193125-20-108751-index.htm |
| 2020-04-27 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1636282/000119312520120950/0001193125-20-120950-index.htm |
| 2020-04-28 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1636282/000119312520123045/0001193125-20-123045-index.htm |
| 2020-06-09 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1636282/000119312520164398/0001193125-20-164398-index.htm |
| 2020-07-06 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1636282/000119312520187891/0001193125-20-187891-index.htm |
| 2020-05-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000120919120026662/0001209191-20-026662-index.htm |
| 2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000120919120035506/0001209191-20-035506-index.htm |
| 2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000120919120035510/0001209191-20-035510-index.htm |
| 2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000120919120035515/0001209191-20-035515-index.htm |
| 2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000120919120035517/0001209191-20-035517-index.htm |
| 2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000120919120035519/0001209191-20-035519-index.htm |
| 2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000120919120035528/0001209191-20-035528-index.htm |
| 2018-07-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459018016855/0001564590-18-016855-index.htm |
| 2018-07-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459018017205/0001564590-18-017205-index.htm |
| 2018-08-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459018020756/0001564590-18-020756-index.htm |
| 2018-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1636282/000156459018020760/0001564590-18-020760-index.htm |
| 2018-09-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459018022572/0001564590-18-022572-index.htm |
| 2018-09-06 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1636282/000156459018022770/0001564590-18-022770-index.htm |
| 2018-10-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459018024097/0001564590-18-024097-index.htm |
| 2018-10-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459018024362/0001564590-18-024362-index.htm |
| 2018-10-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459018024570/0001564590-18-024570-index.htm |
| 2018-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459018028290/0001564590-18-028290-index.htm |
| 2018-11-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1636282/000156459018028293/0001564590-18-028293-index.htm |
| 2018-11-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459018030229/0001564590-18-030229-index.htm |
| 2018-12-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459018030803/0001564590-18-030803-index.htm |
| 2018-12-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459018030817/0001564590-18-030817-index.htm |
| 2019-03-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459019006770/0001564590-19-006770-index.htm |
| 2019-03-07 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1636282/000156459019006771/0001564590-19-006771-index.htm |
| 2019-03-07 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1636282/000156459019006831/0001564590-19-006831-index.htm |
| 2019-03-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459019007016/0001564590-19-007016-index.htm |
| 2019-04-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459019010958/0001564590-19-010958-index.htm |
| 2019-04-22 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1636282/000156459019012157/0001564590-19-012157-index.htm |
| 2019-05-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459019015734/0001564590-19-015734-index.htm |
| 2019-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459019016206/0001564590-19-016206-index.htm |
| 2019-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1636282/000156459019016211/0001564590-19-016211-index.htm |
| 2019-06-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459019022028/0001564590-19-022028-index.htm |
| 2019-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459019028997/0001564590-19-028997-index.htm |
| 2019-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1636282/000156459019028999/0001564590-19-028999-index.htm |
| 2019-09-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459019033820/0001564590-19-033820-index.htm |
| 2019-09-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459019035587/0001564590-19-035587-index.htm |
| 2019-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459019040690/0001564590-19-040690-index.htm |
| 2019-11-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1636282/000156459019040692/0001564590-19-040692-index.htm |
| 2019-12-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459019045077/0001564590-19-045077-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459020000861/0001564590-20-000861-index.htm |
| 2020-01-13 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459020000976/0001564590-20-000976-index.htm |
| 2020-02-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459020005885/0001564590-20-005885-index.htm |
| 2020-02-24 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1636282/000156459020005888/0001564590-20-005888-index.htm |
| 2020-02-24 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1636282/000156459020005895/0001564590-20-005895-index.htm |
| 2020-04-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459020015274/0001564590-20-015274-index.htm |
| 2020-04-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459020015807/0001564590-20-015807-index.htm |
| 2020-04-23 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1636282/000156459020018057/0001564590-20-018057-index.htm |
| 2020-04-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459020018828/0001564590-20-018828-index.htm |
| 2020-04-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459020019249/0001564590-20-019249-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459020022401/0001564590-20-022401-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1636282/000156459020022403/0001564590-20-022403-index.htm |
| 2020-05-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459020026818/0001564590-20-026818-index.htm |
| 2020-05-28 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1636282/000156459020027318/0001564590-20-027318-index.htm |
| 2020-06-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459020028787/0001564590-20-028787-index.htm |
| 2020-07-10 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1636282/000156459020032169/0001564590-20-032169-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459020038650/0001564590-20-038650-index.htm |
| 2020-08-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1636282/000156459020038651/0001564590-20-038651-index.htm |
| 2020-09-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459020043343/0001564590-20-043343-index.htm |
| 2020-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1636282/000156459020050905/0001564590-20-050905-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1636282/000156459020050906/0001564590-20-050906-index.htm |
| 2018-08-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761918001186/0001567619-18-001186-index.htm |
| 2018-08-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761918001566/0001567619-18-001566-index.htm |
| 2018-09-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761918003282/0001567619-18-003282-index.htm |
| 2018-12-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761918007640/0001567619-18-007640-index.htm |
| 2019-02-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919002796/0001567619-19-002796-index.htm |
| 2019-03-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919005835/0001567619-19-005835-index.htm |
| 2019-03-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919005836/0001567619-19-005836-index.htm |
| 2019-03-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919005837/0001567619-19-005837-index.htm |
| 2019-03-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919005839/0001567619-19-005839-index.htm |
| 2019-03-08 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919006484/0001567619-19-006484-index.htm |
| 2019-03-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919006485/0001567619-19-006485-index.htm |
| 2019-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919011561/0001567619-19-011561-index.htm |
| 2019-05-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919011852/0001567619-19-011852-index.htm |
| 2019-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919013069/0001567619-19-013069-index.htm |
| 2019-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919013070/0001567619-19-013070-index.htm |
| 2019-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919013071/0001567619-19-013071-index.htm |
| 2019-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919013072/0001567619-19-013072-index.htm |
| 2019-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919013073/0001567619-19-013073-index.htm |
| 2019-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919013074/0001567619-19-013074-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919013411/0001567619-19-013411-index.htm |
| 2019-10-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919019297/0001567619-19-019297-index.htm |
| 2019-10-23 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919019921/0001567619-19-019921-index.htm |
| 2019-10-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919019922/0001567619-19-019922-index.htm |
| 2019-11-04 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919020398/0001567619-19-020398-index.htm |
| 2019-11-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761919020399/0001567619-19-020399-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761920004315/0001567619-20-004315-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761920004316/0001567619-20-004316-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761920004317/0001567619-20-004317-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761920004318/0001567619-20-004318-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1636282/000156761920004319/0001567619-20-004319-index.htm |
| 2019-02-13 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1636282/999999999519000212/9999999995-19-000212-index.htm |
| 2020-07-14 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1636282/999999999520001803/9999999995-20-001803-index.htm |
| 2019-03-19 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1636282/999999999719001393/9999999997-19-001393-index.htm |
Aeglea BioTherapeutics, Inc (AGLE) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aeglea BioTherapeutics, Inc (AGLE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 253%Institutional Ownership: 9444%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-08-13 | GEORGE GEORGIOU | Director | Buy | 17,333.00 | 7.28 | 126,184.24 | 155,861.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761918001186/0001567619-18-001186-index.htm |
| 2018-08-13 | GEORGE GEORGIOU | Director | Buy | 20,000.00 | 4.73 | 94,600.00 | 175,861.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761918001186/0001567619-18-001186-index.htm |
| 2018-12-07 | Anthony G. Quinn | President & CEO | Buy | 150,000.00 | 4.11 | 616,500.00 | 245,787.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761918007640/0001567619-18-007640-index.htm |
| 2018-12-07 | Anthony G. Quinn | President & CEO | Buy | 3,306.00 | 5.46 | 18,050.76 | 249,093.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761918007640/0001567619-18-007640-index.htm |
| 2018-09-27 | Aaron Schuchart | Chief Business Officer | Sell | 5,900.00 | 9.50 | 56,050.00 | 2,500.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761918003282/0001567619-18-003282-index.htm |
| 2018-12-07 | Anthony G. Quinn | President & CEO | Buy | 18,584.00 | 6.31 | 117,265.04 | 267,677.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761918007640/0001567619-18-007640-index.htm |
| 2019-02-06 | Anthony G. Quinn | President & CEO | Buy | 1,323.00 | 5.46 | 7,223.58 | 269,000.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761919002796/0001567619-19-002796-index.htm |
| 2019-02-06 | Anthony G. Quinn | President & CEO | Buy | 7,433.00 | 6.31 | 46,902.23 | 276,433.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761919002796/0001567619-19-002796-index.htm |
| 2019-02-15 | Anthony G. Quinn | President & CEO | Buy | 719.00 | 7.10 | 5,103.46 | 277,152.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761919011561/0001567619-19-011561-index.htm |
| 2019-05-15 | Anthony G. Quinn | President & CEO | Buy | 6,256.00 | 6.76 | 42,269.29 | 283,408.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761919011561/0001567619-19-011561-index.htm |
| 2019-05-16 | Anthony G. Quinn | President & CEO | Buy | 5,520.00 | 6.83 | 37,690.56 | 288,928.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761919011561/0001567619-19-011561-index.htm |
| 2019-05-17 | Anthony G. Quinn | President & CEO | Buy | 6,218.00 | 6.65 | 41,335.40 | 295,146.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761919011561/0001567619-19-011561-index.htm |
| 2019-05-20 | Anthony G. Quinn | President & CEO | Buy | 8,989.00 | 6.56 | 58,922.90 | 304,135.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761919011852/0001567619-19-011852-index.htm |
| 2019-05-21 | Anthony G. Quinn | President & CEO | Buy | 13,794.00 | 6.89 | 94,981.35 | 317,929.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761919011852/0001567619-19-011852-index.htm |
| 2019-05-22 | Anthony G. Quinn | President & CEO | Buy | 3,809.00 | 6.86 | 26,128.22 | 321,738.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761919011852/0001567619-19-011852-index.htm |
| 2019-06-12 | Anthony G. Quinn | President & CEO | Buy | 12,217.00 | 6.11 | 74,704.51 | 333,955.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761919013411/0001567619-19-013411-index.htm |
| 2019-06-13 | Anthony G. Quinn | President & CEO | Buy | 14,406.00 | 6.17 | 88,836.04 | 348,361.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761919013411/0001567619-19-013411-index.htm |
| 2019-06-14 | Anthony G. Quinn | President & CEO | Buy | 5,282.00 | 6.23 | 32,912.67 | 353,643.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761919013411/0001567619-19-013411-index.htm |
| 2019-10-04 | Anthony G. Quinn | President & CEO | Buy | 662.00 | 5.46 | 3,614.52 | 354,305.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761919019297/0001567619-19-019297-index.htm |
| 2019-10-04 | Anthony G. Quinn | President & CEO | Buy | 17,603.00 | 6.31 | 111,074.93 | 371,908.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761919019297/0001567619-19-019297-index.htm |
| 2020-04-30 | Anthony G. Quinn | President & CEO | Buy | 165,000.00 | 4.75 | 783,750.00 | 538,469.00 | https://www.sec.gov/Archives/edgar/data/1636282/000120919120026662/0001209191-20-026662-index.htm |
| 2018-07-11 | Anthony G. Quinn | Interim CEO | Buy | 3,307.00 | 5.46 | 18,056.22 | 53,927.00 | https://www.sec.gov/Archives/edgar/data/1636282/000114036118032316/0001140361-18-032316-index.htm |
| 2018-07-12 | Anthony G. Quinn | Interim CEO | Buy | 24,000.00 | 7.04 | 168,960.00 | 77,927.00 | https://www.sec.gov/Archives/edgar/data/1636282/000114036118032462/0001140361-18-032462-index.htm |
| 2018-09-27 | Aaron Schuchart | Chief Business Officer | Sell | 100.00 | 9.55 | 955.00 | 8,400.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761918003282/0001567619-18-003282-index.htm |
| 2018-08-17 | Aaron Schuchart | Chief Business Officer | Buy | 8,500.00 | 3.50 | 29,750.00 | 8,500.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761918001566/0001567619-18-001566-index.htm |
| 2018-07-12 | Anthony G. Quinn | Interim CEO | Buy | 14,866.00 | 6.31 | 93,804.46 | 92,793.00 | https://www.sec.gov/Archives/edgar/data/1636282/000114036118032462/0001140361-18-032462-index.htm |
| 2018-02-15 | Anthony G. Quinn | President & CEO | Buy | 2,000.00 | 6.02 | 12,040.00 | 94,793.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761918007640/0001567619-18-007640-index.htm |
| 2018-08-15 | Anthony G. Quinn | President & CEO | Buy | 994.00 | 9.13 | 9,075.22 | 95,787.00 | https://www.sec.gov/Archives/edgar/data/1636282/000156761918007640/0001567619-18-007640-index.htm |